The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Impax Laboratories missed estimates on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly and GAAP earnings per share increased.
Gross margins grew, operating margins contracted, net margins shrank.
Impax Laboratories logged revenue of $145.6 million. The 14 analysts polled by S&P Capital IQ wanted to see revenue of $161.4 million on the same basis. GAAP reported sales were 21% higher than the prior-year quarter's $119.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.48. The 14 earnings estimates compiled by S&P Capital IQ averaged $0.48 per share. GAAP EPS of $0.29 for Q3 were 12% higher than the prior-year quarter's $0.26 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 53.6%, 130 basis points better than the prior-year quarter. Operating margin was 20.0%, 290 basis points worse than the prior-year quarter. Net margin was 13.8%, 60 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $166.2 million. On the bottom line, the average EPS estimate is $0.44.
Next year's average estimate for revenue is $637.2 million. The average EPS estimate is $2.03.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 169 members out of 185 rating the stock outperform, and 16 members rating it underperform. Among 47 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 43 give Impax Laboratories a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Impax Laboratories is outperform, with an average price target of $25.59.
- Add Impax Laboratories to My Watchlist.